Literature DB >> 31935730

Salivary aldosterone, cortisol and their morning to evening slopes in patients with depressive disorder and healthy subjects: acute episode and follow up six months after reaching remission.

Lubomira Izakova, Natasa Hlavacova, Viktor Segeda, Daniela Kapsdorfer, Eva Morovicsova, Daniela Jezova.   

Abstract

BACKGROUND/
OBJECTIVE: Cortisol is thought to be involved in the pathophysiology of affective disorders. Less attention has been given to other neuroendocrine factors. The aim of the present study was to test the hypothesis that adrenocortical steroids aldosterone and cortisol show different dynamic changes in the course of clinical depression with the assumption that aldosterone is a state marker of depression.
METHODS: A total of 78 adult subjects (39 patients with depressive disorder and 39 healthy controls) participated in a prospective non-interventional clinical study. Patients were investigated at the time of an acute episode and six months after reaching remission. The clinical and personal characteristics, morning and evening salivary concentrations of aldosterone and cortisol were evaluated.
RESULTS: Patients with an acute depressive episode exhibited higher evening aldosterone and lower morning cortisol concentrations compared to healthy subjects. In these patients, both hormone concentrations showed flatter morning to evening slopes. Salivary aldosterone, but not cortisol concentrations were lower in patients six months after reaching remission compared to those in the acute state. Similarly, six months of remission resulted in a steeper morning to evening slope of salivary aldosterone compared to the acute state. Cortisol rhythm remained dysregulated. A significant negative correlation between trait anxiety scores and morning cortisol concentrations in patients at six months of clinical remission was observed.
CONCLUSION: Diurnal changes in salivary aldosterone concentrations appear to be a state marker, whilst those of cortisol a trait marker of depression.
© 2020 S. Karger AG, Basel.

Entities:  

Year:  2020        PMID: 31935730     DOI: 10.1159/000505921

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  4 in total

1.  Adjunct Therapy With Glycyrrhiza Glabra Rapidly Improves Outcome in Depression-A Pilot Study to Support 11-Beta-Hydroxysteroid Dehydrogenase Type 2 Inhibition as a New Target.

Authors:  Harald Murck; Lisa Lehr; Johannes Hahn; Matthias C Braunisch; Daniela Jezova; Maxim Zavorotnyy
Journal:  Front Psychiatry       Date:  2020-12-10       Impact factor: 4.157

2.  Probing Neuro-Endocrine Interactions Through Remote Magnetothermal Adrenal Stimulation.

Authors:  Lisa Y Maeng; Dekel Rosenfeld; Gregory J Simandl; Florian Koehler; Alexander W Senko; Junsang Moon; Georgios Varnavides; Maria F Murillo; Adriano E Reimer; Aaron Wald; Polina Anikeeva; Alik S Widge
Journal:  Front Neurosci       Date:  2022-06-23       Impact factor: 5.152

3.  Stress Hormones Cortisol and Aldosterone, and Selected Markers of Oxidative Stress in Response to Long-Term Supplementation with Omega-3 Fatty Acids in Adolescent Children with Depression.

Authors:  Henrieta Oravcova; Barbora Katrencikova; Iveta Garaiova; Zdenka Durackova; Jana Trebaticka; Daniela Jezova
Journal:  Antioxidants (Basel)       Date:  2022-08-10

4.  Delta-Opioid Receptors Play a Role in the Control of Selected Parameters Related to Stress and Brain Plasticity Under Non-stress and/or Stress Conditions.

Authors:  P Chomanic; L Karailievova; J Graban; D Jezova
Journal:  Cell Mol Neurobiol       Date:  2021-03-08       Impact factor: 5.046

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.